Search results for "mediator"

showing 10 items of 339 documents

Mechanism of interaction of betanin and indicaxanthin with human myeloperoxidase and hypochlorous acid.

2005

Hypochlorous acid (HOCl) is the most powerful oxidant produced by human neutrophils and contributes to the damage caused by these inflammatory cells. It is produced from H2O2 and chloride by the heme enzyme myeloperoxidase (MPO). Based on findings that betalains provide antioxidant and anti-inflammatory effects, we performed the present kinetic study on the interaction between the betalains, betanin and indicaxanthin, with the redox intermediates, compound I and compound II of MPO, and its major cytotoxic product HOCl. It is shown that both betalains are good peroxidase substrates for MPO and function as one-electron reductants of its redox intermediates, compound I and compound II. Compoun…

AntioxidantIndolesHypochlorous acidStereochemistryPyridinesmedicine.medical_treatmentBiophysicsIn Vitro TechniquesBiochemistryMedicinal chemistryRedoxAntioxidantsSubstrate Specificitychemistry.chemical_compoundBetalainmedicineHumansMolecular BiologyBetaninPeroxidasebiologyBetanin myeloperoxidase nitrite low-density lipoproteins atherosclerosisCell BiologyOxidantsBetaxanthinsHypochlorous AcidKineticschemistryMyeloperoxidasebiology.proteinFerricBetacyaninsInflammation MediatorsIndicaxanthinOxidation-Reductionmedicine.drugBiochemical and biophysical research communications
researchProduct

The anti-inflammatory fungal compound (S)-curvularin reduces proinflammatory gene expression in an in vivo model of rheumatoid arthritis.

2012

In previous studies, we identified the fungal macrocyclic lactone (S)-curvularin (SC) as an anti-inflammatory agent using a screening system detecting inhibitors of the Janus kinase/signal transducer and activator of transcription pathway. The objective of the present study was to investigate whether SC is able to decrease proinflammatory gene expression in an in vivo model of a chronic inflammatory disease. Therefore, the effects of SC and dexamethasone were compared in the model of collagen-induced arthritis (CIA) in mice. Total genomic microarray analyses were performed to identify SC target genes. In addition, in human C28/I2 chondrocytes and MonoMac6 monocytes, the effect of SC on proi…

ArthritisMice TransgenicBiologyProinflammatory cytokineArthritis RheumatoidMiceIn vivomedicineAnimalsHumansCells CulturedCell Line TransformedPharmacologyRegulation of gene expressionAnti-Inflammatory Agents Non-SteroidalCurvularinmedicine.diseaseCompound sDisease Models AnimalGene Expression RegulationMice Inbred DBAImmunologyCancer researchSTAT proteinMolecular MedicineZearalenoneInflammation MediatorsJanus kinaseThe Journal of pharmacology and experimental therapeutics
researchProduct

Minimal clinically important difference for asthma endpoints: an expert consensus report

2020

Minimal clinically important difference (MCID) can be defined as the smallest change or difference in an outcome measure that is perceived as beneficial and would lead to a change in the patient's medical management.The aim of the current expert consensus report is to provide a “state-of-the-art” review of the currently available literature evidence about MCID for end-points to monitor asthma control, in order to facilitate optimal disease management and identify unmet needs in the field to guide future research.A series of MCID cut-offs are currently available in literature and validated among populations of asthmatic patients, with most of the evidence focusing on outcomes as patient repo…

Asthma asthma management minimal clinically important difference end-pointsPulmonary and Respiratory Medicinemedicine.medical_specialtyConsensusDelphi TechniqueEndpoint DeterminationBronchoconstrictionMEDLINEDelphi methodSocio-culturaleSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOminimal clinically important difference; asthma; lung function; biomarkersMCID03 medical and health sciences0302 clinical medicinePredictive Value of TestsmedicineHumansAnti-Asthmatic Agents030212 general & internal medicineDisease management (health)Intensive care medicineLungAsthmalcsh:RC705-779business.industryMinimal clinically important differenceminimal clinically important differenceExpert consensusend-pointslcsh:Diseases of the respiratory systemmedicine.diseaseMCID asthmaAsthmaTreatment Outcome030228 respiratory systemPredictive value of testsEndpoint DeterminationInflammation MediatorsSymptom AssessmentbusinessBiomarkersasthma managementEuropean Respiratory Review
researchProduct

STAT6: its role in interleukin 4-mediated biological functions.

1997

Interleukin (IL) 4 is known to be a cytokine which plays a central role in the regulation of immune response. Studies on cytokine signal transduction have clarified the mechanism by which IL4 exerts its functions. Two cytoplasmic proteins, signal transducer and activator of transcription (STAT) 6 and IL4-induced phosphotyrosine substrate/insulin receptor substrate 2 (4PS/IRS2), are activated in IL4 signal transduction. Recent studies from STAT6-deficient mice have revealed the essential role of STAT6 in IL4-mediated biological actions. In addition, STAT6 has also been demonstrated to be important for the functions mediated by IL13, which is related to IL4. IL4 and IL13 have been shown to in…

BiologyMediatorimmune system diseasesAntigens CDparasitic diseasesDrug DiscoveryAnimalsHumansskin and connective tissue diseasesGenetics (clinical)Interleukin 4STAT6Interleukin-13Interleukinhemic and immune systemsReceptors InterleukinIRS2Cell biologyReceptors Interleukin-4Interleukin 13ImmunologySTAT proteinTrans-ActivatorsMolecular MedicineInterleukin-4Signal transductionSTAT6 Transcription FactorSignal TransductionJournal of molecular medicine (Berlin, Germany)
researchProduct

N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A…

2011

64% of chronic obstructive pulmonary disease (COPD) exacerbations are caused by respiratory infections including influenza (strains A and B) and respiratory syncytial virus (RSV). They affect the airway epithelium increasing inflammatory and apoptosis events through mechanisms involving ROS generation, and induce the release of mucins from epithelial cells that are involved in the deterioration of the patient's health during the course of the disease. The antioxidant NAC has proved useful in the management of COPD reducing symptoms, exacerbations and accelerated lung function decline. It has been shown to inhibit influenza virus replication and to diminish the release of inflammatory and ap…

BiologyMucin 5ACmedicine.disease_causeVirus ReplicationBiochemistryp38 Mitogen-Activated Protein KinasesVirusCell LinePulmonary Disease Chronic ObstructivemedicineHumansInterleukin 8PhosphorylationPharmacologyA549 cellMucinNF-kappa BAcetylcysteineRespiratory Syncytial VirusesPulmonary AlveoliInfluenza B virusRespiratory syncytial virus (RSV)Viral replicationApoptosisInfluenza A virusImmunologyRespiratory epitheliumInflammation MediatorsBiochemical pharmacology
researchProduct

Chronic exposure of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces an obesogenic effect in C57BL/6J mice fed a high fat diet

2017

IF 3.582; International audience; Contaminant involvement in the pathophysiology of obesity is widely recognized. It has been shown that low dose and chronic exposure to endocrine disruptor compounds (EDCs) potentiated diet- induced obesity. High and acute exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a persistent organic pollutant (POP) and an EDC with anti-estrogenic property, causes wasting syndrome . However at lower doses, the TCDD metabolic effects remain poorly understood. We investigated the obesogenic effect during chronic exposure of TCDD at 1μg/kg body weight (bw)/week in adult C57BL/6J mice fed with a high fat diet (HFD) and exposed from 10 to 42 weeks old to TCDD or e…

Blood GlucoseLeptinMale0301 basic medicineTCDDPolychlorinated DibenzodioxinsTime FactorsAdipose tissue010501 environmental sciencesToxicology01 natural sciencesBasic Helix-Loop-Helix Transcription FactorsInsulinAdiposity2. Zero hunger[ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism3. Good healthLiverEndocrine disruptorReceptors AndrogenCytokinesEnvironmental PollutantsFemaleInflammation Mediatorsmedicine.symptomStearoyl-CoA Desaturasemedicine.medical_specialtyLipolysisInflammationchronic exposureIntra-Abdominal FatDiet High-FatRisk Assessment03 medical and health sciencesSex FactorsobesogenInternal medicinemedicineAnimalsEndocrine systemObesityRNA MessengerWasting SyndromeTriglycerides0105 earth and related environmental sciencesbusiness.industrymedicine.diseaseObesityMice Inbred C57BL030104 developmental biologyEndocrinologyReceptors Aryl HydrocarbonInsulin ResistancebusinessBiomarkersObesogenDrug metabolism
researchProduct

Does Glycemic Control Modulate the Impairment of NLRP3 Inflammasome Activation in Type 2 Diabetes?

2019

Since mitochondrial dysfunction is associated with NOD-like receptor family protein 3 (NLRP3) activation in type 2 diabetes (T2D), which can eventually lead to an impaired immune response, we set out to determine if glycemic control modulates the effects of T2D on the NLRP3 inflammasome. We have studied leukocytes from 61 diabetic patients [25 with glycated hemoglobin (HbA(1c)) 7% and 36 with HbA(1c) 8%] and 40 healthy controls. Total and mitochondrial reactive oxygen species (ROS) production was enhanced in T2D patients, and mitochondrial ROS was more pronounced in those with poor glycemic control. Levels of gene and protein expression of NLRP3 were decreased in both diabetic groups and mo…

Blood GlucoseMale0301 basic medicineMitochondrial ROSendocrine system diseasesInflammasomesPhysiologyClinical BiochemistryType 2 diabetesmedicine.disease_causeBiochemistrychemistry.chemical_compoundGene expressionoxidative stressGeneral Environmental Scienceintegumentary systemInterleukinInflammasomeMiddle AgedMitochondriaglycaemic controlCytokinesFemaletype 2 diabetesInflammation MediatorsSignal Transductionmedicine.drugmedicine.medical_specialty03 medical and health sciencesmitochondrial functionInternal medicineNLR Family Pyrin Domain-Containing 3 ProteinmedicineHumansBody Weights and MeasuresMolecular BiologyAgedGlycemicGlycated Hemoglobin030102 biochemistry & molecular biologybusiness.industrynutritional and metabolic diseasesCell Biologymedicine.diseaseNLRP3 inflammasome030104 developmental biologyEndocrinologyDiabetes Mellitus Type 2chemistryGeneral Earth and Planetary SciencesGlycated hemoglobinReactive Oxygen SpeciesbusinessBiomarkersOxidative stressAntioxidants & Redox Signaling
researchProduct

Effects of GLP-1 receptor agonists on myokine levels and pro-inflammatory cytokines in patients with type 2 diabetes mellitus.

2021

Background and aims: To evaluate the change in circulating serum irisin and interleukin-6 (IL-6), in patients with type 2 diabetes mellitus (T2DM) after 6 and 12 months of GLP-1 treatment. Methods and results: Eighty-five patients with T2DM inadequately controlled with insulin or other hypoglycaemic drugs were added to dulaglutide (N° = 44) and liraglutide (N° = 41) treatment. After 6 months of GLP-1 analogues a significant decrease in BMI (p < 0.001), waist circumference (WC) (p < 0.001), fasting blood glucose (p < 0.001), HbA1c (p < 0.001), total cholesterol (p < 0.001), LDL-cholesterol (p = 0.003), triglycerides (p = 0.017), IL-6 (p = 0.045) and a significant increase in s…

Blood GlucoseMaleIrisinmedicine.medical_specialtyTime FactorsEndocrinology Diabetes and Metabolismmedicine.medical_treatmentRecombinant Fusion ProteinsGlucagon-Like PeptidesMedicine (miscellaneous)IncretinsGlucagon-Like Peptide-1 ReceptorSettore MED/13 - EndocrinologiaProinflammatory cytokineAdipokineInternal medicineMyokinemedicineHumansHypoglycemic AgentsInsulinIn patientDulaglutideGlucagon-like peptide 1 receptorAgedNutrition and DieteticsLiraglutidebusiness.industryInterleukin-6InsulinType 2 Diabetes MellitusLiraglutideMiddle AgedFibronectinsImmunoglobulin Fc FragmentsSettore BIO/12 - Biochimica Clinica E Biologia Molecolare ClinicaEndocrinologyCholesterolTreatment OutcomeDiabetes Mellitus Type 2DulaglutideDrug Therapy CombinationFemaleInflammation MediatorsWaist CircumferenceCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Eicosapentaenoic acid modulates fatty acid metabolism and inflammation in Psammomys obesus.

2015

Abstract The desert gerbil, Psammomys obesus, is a unique polygenic animal model of metabolic syndrome (insulin resistance, obesity and type 2 diabetes), and these pathological conditions resemble to those in human beings. In this study, the animals were fed ad libitum either a natural diet (ND) which contained desertic halophile plants or a standard laboratory diet (STD) or a diet which contained eicosapentaenoic acid (EPA), hence, termed as EPA diet (EPAD). In EPAD, 50% of total lipid content was replaced by EPA oil. By employing real-time PCR, we assessed liver expression of key genes involved in fatty acid metabolism such as PPAR-α, SREBP-1c, LXR-α and CHREBP. We also studied the expres…

Blood GlucoseMalemedicine.medical_specialtymedicine.medical_treatmentInterleukin-1betaAdipose tissueGene ExpressionBiologyBiochemistrychemistry.chemical_compoundInsulin resistanceInternal medicinemedicineAnimalsInsulinPPAR alphaRNA MessengerTriglyceridesLiver X Receptorschemistry.chemical_classificationFatty acid metabolismReverse Transcriptase Polymerase Chain ReactionTumor Necrosis Factor-alphaInsulinBody WeightFatty AcidsGeneral Medicinebiology.organism_classificationmedicine.diseaseLipid MetabolismOrphan Nuclear ReceptorsEicosapentaenoic acidEndocrinologychemistryAdipose TissueEicosapentaenoic AcidLiverlipids (amino acids peptides and proteins)PsammomysMetabolic syndromeInflammation MediatorsGerbillinaeSterol Regulatory Element Binding Protein 1Polyunsaturated fatty acidBiochimie
researchProduct

The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model b…

2014

Objective In diabetes, vascular dysfunction is characterized by impaired endothelial function due to increased oxidative stress. Empagliflozin, as a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i), offers a novel approach for the treatment of type 2 diabetes by enhancing urinary glucose excretion. The aim of the present study was to test whether treatment with empagliflozin improves endothelial dysfunction in type I diabetic rats via reduction of glucotoxicity and associated vascular oxidative stress. Methods Type I diabetes in Wistar rats was induced by an intravenous injection of streptozotocin (60 mg/kg). One week after injection empagliflozin (10 and 30 mg/kg/d) was adminis…

Blood GlucoseMalemedicine.medical_treatmentReceptor for Advanced Glycation End Productslcsh:MedicineGene ExpressionType 2 diabetesmedicine.disease_causeVascular MedicineGlucosidesMedicine and Health SciencesMedicineInsulinEndothelial dysfunctionReceptors Immunologiclcsh:ScienceMultidisciplinaryType 1 DiabetesCytokinesInflammation Mediatorsmedicine.drugSignal TransductionResearch Articlemedicine.medical_specialtyCardiologyBlood sugarStreptozocinCardiovascular PharmacologyDiabetes Mellitus ExperimentalDiabetes ComplicationsInternal medicineDiabetes mellitusEmpagliflozinDiabetes MellitusAnimalsRNA MessengerVascular DiseasesBenzhydryl CompoundsSodium-Glucose Transporter 2 InhibitorsPharmacologybusiness.industryInsulinlcsh:RHemodynamicsStreptozotocinmedicine.diseaseRatsOxidative StressEndocrinologyGlucoseMetabolic Disorderslcsh:QbusinessOxidative stressDiabetic AngiopathiesPloS one
researchProduct